Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/9043
ALLOIMMUNIZATION AND CLINICAL PROFILE OF SICKLE CELL DISEASE PATIENTS FROM SALVADOR-BRAZIL.
Transfusão de Eritrócitos/efeitos adversos
Isoanticorpos
Adolescente
Adulto
Anemia Falciforme/complicações
Brasil/epidemiologia
Teste de Coombs
Estudos Transversais
Feminino
Humanos
Úlcera da Perna/complicações
Masculino
Meia-Idade
Ambulatório Hospitalar/estatística & dados numéricos
Prevalência
Estudos Retrospectivos
Acidente Vascular Cerebral/complicações
Adulto Jovem
Autor(es)
Afiliação
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Medicine School. Bahia Foundation for Science Development. Salvador, BA, Brasil
Medicine School. Bahia Foundation for Science Development. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Medicine School. Bahia Foundation for Science Development. Salvador, BA, Brasil
Medicine School. Bahia Foundation for Science Development. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Hematology and Hemotherapy Center of Bahia. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Resumo em Inglês
Sickle cell disease (SCD) is an important public health issue in Bahia, Brazil. Erythrocyte transfusions may reduce morbidity of SCD, however, they are associated with numerous risks. Among other risk categories, alloimmunization to red cell antigens may result from transfusions. The aim of this study was to compare the clinical profile of transfused adult SCD patients with and without alloantibodies. The study included 108 patients (105 homozygous SS and three with hemoglobinopathy SC), followed in the Outpatient Unit of the Hematology and Hemotherapy Center of Bahia. A retrospective review of clinical records of adult SCD patients who received at least three red blood cell transfusions from 2004 to 2007 was performed. Transfusion units were phenotypically matched for ABH-D and C,c,E,e, and K antigens. Alloimmunization developed in 56 patients (53 SS and three SC). The most prevalent alloantibodies were anti-E, anti-K, and anti-C (39.3%, 21.4%, and 16.1%, respectively). Age, sex and positive antiglobulin test displayed statistically significant differences. Prevalence of clinical complications such as leg ulcers, stroke, and others did not show differences between groups. In conclusion, alloimmunization did not significantly modify the clinical outcomes of SCD patients from Bahia, Brazil.
DeCS
Anemia Falciforme/terapiaTransfusão de Eritrócitos/efeitos adversos
Isoanticorpos
Adolescente
Adulto
Anemia Falciforme/complicações
Brasil/epidemiologia
Teste de Coombs
Estudos Transversais
Feminino
Humanos
Úlcera da Perna/complicações
Masculino
Meia-Idade
Ambulatório Hospitalar/estatística & dados numéricos
Prevalência
Estudos Retrospectivos
Acidente Vascular Cerebral/complicações
Adulto Jovem
Compartilhar